The European Commission's decision on approval is expected in the second half of January 2025. Eylea is used to treat neovascular age-related macular degeneration and other severe retinal diseases.

Dr. Stefan Glombitza, CEO of Formycon AG, commented: “The EU approval of FYB203, our biosimilar for Eylea ®, marks another milestone for Formycon and is based on the expertise and dedication of our ...

UnitedHealthcare has agreed to a $2.5 million settlement in a class action lawsuit affecting just over 12,000 individuals. The lawsuit alleges UnitedHealthcare made unauthorized telemarketing calls in ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Plaintiff pursues claims under Sections ... drug distributors in the form of reimbursed credit card fees. As a result, the DOJ alleges that the ASP of Regeneron’s Eylea drug was inflated ...

The stock has underperformed the sector and the S&P 500 Index during this timeframe. Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ sentiment.

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...

Note: Another version of Eylea is available called Eylea HD. This is a higher dose, longer-acting form of the drug, and it’s used to treat wet AMD, diabetic retinopathy, and diabetic macular ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement ... Report on Form 10-Q for the third quarter ...

UBS noted that the stock’s valuation, trading at 15x earnings, reflects its innovation but sees investors pivoting to peers with stronger short-term growth. Regeneron shares are trading near pre ...